|
|
|
|
| LEADER |
01440nam a2200313 u 4500 |
| 001 |
EB001872298 |
| 003 |
EBX01000000000000001035669 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Ixekizumab (Taltz) (Eli Lilly Canada Inc.)
|
| 246 |
3 |
1 |
|a Clinical Review Report for Taltz
|
| 250 |
|
|
|a Version: Final (with redactions)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, August 2018
|
| 300 |
|
|
|a 1 PDF file (111 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized
|
| 653 |
|
|
|a Dermatologic Agents / therapeutic use
|
| 653 |
|
|
|a Arthritis, Psoriatic / drug therapy
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK540011
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a The objective of this review is to perform a systematic review of the beneficial and harmful effects of ixekizumab (Taltz) at the recommended dose for the treatment of adult patients with active psoriatic arthritis
|